News
ESMO: Opdivo chases Keytruda in perioperative lung cancer
Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a
